A paradigm shift in early-stage breast cancer treatment could spare thousands of women from surgery while maintaining excellent outcomes. This approach challenges the century-old surgical standard that has defined breast cancer care, potentially transforming how we treat the most common form of the disease in older women.
Twenty women with small, hormone-positive breast cancers received three months of hormone therapy followed by five sessions of precisely targeted radiation therapy (SABR). Six to twelve months later, tissue biopsies revealed complete tumor elimination in 53% of participants, with another 37% showing near-complete response. Among the 12 patients who avoided surgery entirely, three-year progression-free survival reached 92% with no breast cancer recurrences during a median 45-month follow-up period.
This non-surgical strategy represents a calculated risk worth taking for carefully selected patients. Early-stage, hormone receptor-positive breast cancers already have exceptional outcomes with standard treatment, making them ideal candidates for de-escalation. The 53% complete response rate, while promising, means nearly half still required surgical intervention after radiation failed to eliminate all cancer cells. However, the approach mirrors successful paradigms in other cancers where radiation has replaced surgery for localized disease. The study's small size and single-institution design limit broader applicability, but the results justify larger randomized trials. For women over 70 facing low-risk breast cancer, this could offer a gentler alternative to lumpectomy while preserving cure rates—a meaningful advance in personalized cancer care that prioritizes both survival and quality of life.